Anavex outlines progress in Alzheimer’s, rare disease studies with cash runway into 2028
Anavex reported a business update and financial results for the third fiscal quarter ended 30 June. The company has submitted all data from its Alzheimer’s disease clinical trials to a newly opened Alzheimer’s IND and intends to use EMA feedback and prior FDA interactions to inform a planned Phase 3
<p>Anavex reported a business update and financial results for the third fiscal quarter ended 30 June. The company has submitted all data from its Alzheimer’s disease clinical trials to a newly opened Alzheimer’s IND and intends to use EMA feedback and prior FDA interactions to inform a planned Phase 3</p>